High-grade Recurrence-Free Survival by Treatment Group
urothelial cancer, end-stage bladder cancer symptoms, muscle-invasive bladder cancer
EVENTS, RECURRENCE, METASTATIC BLADDER CANCER
BCG indicates bacillus Calmette-Guérin; and Gem/Doce, gemcitabine and docetaxel.There were 27 progression events; of those, 3 occurred in the gemcitabine and docetaxel group and 24 occurred in the BCG group. In the gemcitabine and docetaxel group, 2 patients underwent cystectomy for end-stage bladder cancer symptoms, and 1 patient developed metastatic urothelial cancer. In the BCG group, 6 patients underwent radical cystectomy for recurrent NMIBC, 8 underwent cystectomy after developing muscle-invasive bladder cancer (1 partial cystectomy), 1 developed muscle-invasive bladder cancer but did not pursue radical cystectomy, 1 underwent radical cystectomy for end-stage bladder cancer symptoms, and 8 died of metastatic bladder cancer. Pathological findings after cystectomy are summarized in the eTable in After adjusting for age, sex, treatment year, and presence of CIS, treatment with gemcitabine and docetaxel was associated with a lower risk of recurrence (hazard ratio [HR], 0.56; 95% CI, 0.34-0.92; 